Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
Featured trial
DE-117 Spectrum 5 Study

Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost/non-responder subjects diagnosed with POAG or OHT &nbsp

glaucoma
corrected visual acuity
brimonidine tartrate ophthalmic solution
intraocular pressure
latanoprost
  • 73 views
  • 24 Jun, 2021
  • 1 location
Featured trial
A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)

-angle glaucoma.Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months

glaucoma
corrected visual acuity
brimonidine tartrate ophthalmic solution
intraocular pressure
latanoprost
  • 2 views
  • 24 Jun, 2021
  • 1 location
Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

Prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TearClear latanoprost Ophthalmic

  • 0 views
  • 26 Dec, 2021
  • 10 locations
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

  • 0 views
  • 06 Apr, 2021
  • 1 location
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

-angle glaucoma. In the adaptive dose selection phase of the trial, subjects will be randomized in a 1:1:1 ratio to one of two doses of NCX 470 (0.065% or 0.1%) or to latanoprost 0.005%. Following the

glaucoma
hypertension
corrected visual acuity
brimonidine tartrate ophthalmic solution
intraocular pressure
  • 0 views
  • 05 Apr, 2021
  • 2 locations
Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant in adults who have Primary Open Angle Glaucoma.

primary open angle glaucoma
corrected visual acuity
brimonidine tartrate ophthalmic solution
latanoprost
diabetic retinopathy
  • 32 views
  • 31 Dec, 2021
  • 10 locations
Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

The aim of this research study is to assess the safety and feasibility of lowering intraocular pressure (IOP) using an experimental study drug, JV-GL1.

  • 1 views
  • 02 Apr, 2021
  • 1 location
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

Glaucoma is a major cause of blindness. The inability to predict a patient's IOP response to medications is a critical barrier for the clinician to consistently provide highly effective IOP-based treatments. Current trial-and-error approaches to glaucoma management are inefficient and have not addressed this barrier as there are no predictive …

glaucoma
pigmentary glaucoma
gonioscopy
beta blockers
visual field tests
  • 0 views
  • 08 Mar, 2021
  • 3 locations
Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study

Participants were randomised to receive benzalkonium chloride-containing latanoprost (Xalatan) or preservative-free bimatoprost (Lumigan). Through this study, the investigators would like to

  • 0 views
  • 30 May, 2021
  • 1 location